July 16, 2020
NIH, Moderna’s COVID-19 vaccine headed to Phase III trial
Editor's Note
Researchers testing a COVID-19 vaccine being developed by Dr Anthony Fauci’s team at the National Institutes of Health (NIH) and Moderna Inc, reported July 14 that the vaccine was able to produce neutralizing antibodies in the 45 trial participants inoculated in March.
Moderna is scheduled to launch a late-stage trial to evaluate the vaccine in 30,000 volunteers at the end of July.
Free Daily News
- Study: Long working hours alter brain regions tied to emotion, cognition
- Survey: Burnout, rigid schedules push nurses to leave
- UCLA surgeons perform world’s first bladder transplant
- AHA urges HHS to cut regulations that burden hospitals and staff
- Commentary: Overlooking, underfunding perioperative mental health threatens patients
- Study: Fewer men undergo unnecessary prostate cancer surgery amid rise in active surveillance
- OpenAI benchmarking tool tests healthcare LLMs
- Healthgrades recognizes top 15% of hospitals for patient experience in 2025
- Q1 reports show climb in outpatient surgical volume, diverging trends at Surgery Partners, Ardent Health
- Study: SGLT2 inhibitors raise postop euglycemic ketoacidosis risk but lower mortality
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement